IBDEI0G9 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16288,1,3,0)
 ;;=3^Malig Neop Skin,Unspec
 ;;^UTILITY(U,$J,358.3,16288,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,16288,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,16289,0)
 ;;=C48.2^^64^784^14
 ;;^UTILITY(U,$J,358.3,16289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16289,1,3,0)
 ;;=3^Malig Neop Peritoneum,Unspec
 ;;^UTILITY(U,$J,358.3,16289,1,4,0)
 ;;=4^C48.2
 ;;^UTILITY(U,$J,358.3,16289,2)
 ;;=^5001122
 ;;^UTILITY(U,$J,358.3,16290,0)
 ;;=C38.4^^64^784^15
 ;;^UTILITY(U,$J,358.3,16290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16290,1,3,0)
 ;;=3^Malig Neop Pleura
 ;;^UTILITY(U,$J,358.3,16290,1,4,0)
 ;;=4^C38.4
 ;;^UTILITY(U,$J,358.3,16290,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,16291,0)
 ;;=C44.92^^64^784^19
 ;;^UTILITY(U,$J,358.3,16291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16291,1,3,0)
 ;;=3^SCC of Skin,Unspec
 ;;^UTILITY(U,$J,358.3,16291,1,4,0)
 ;;=4^C44.92
 ;;^UTILITY(U,$J,358.3,16291,2)
 ;;=^5001093
 ;;^UTILITY(U,$J,358.3,16292,0)
 ;;=C49.9^^64^784^13
 ;;^UTILITY(U,$J,358.3,16292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16292,1,3,0)
 ;;=3^Malig Neop Connective & Soft Tissue,Unspec
 ;;^UTILITY(U,$J,358.3,16292,1,4,0)
 ;;=4^C49.9
 ;;^UTILITY(U,$J,358.3,16292,2)
 ;;=^5001136
 ;;^UTILITY(U,$J,358.3,16293,0)
 ;;=C72.0^^64^784^17
 ;;^UTILITY(U,$J,358.3,16293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16293,1,3,0)
 ;;=3^Malig Neop Spinal Cord
 ;;^UTILITY(U,$J,358.3,16293,1,4,0)
 ;;=4^C72.0
 ;;^UTILITY(U,$J,358.3,16293,2)
 ;;=^267292
 ;;^UTILITY(U,$J,358.3,16294,0)
 ;;=C72.1^^64^784^12
 ;;^UTILITY(U,$J,358.3,16294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16294,1,3,0)
 ;;=3^Malig Neop Cauda Equina
 ;;^UTILITY(U,$J,358.3,16294,1,4,0)
 ;;=4^C72.1
 ;;^UTILITY(U,$J,358.3,16294,2)
 ;;=^5001298
 ;;^UTILITY(U,$J,358.3,16295,0)
 ;;=C92.40^^64^785^15
 ;;^UTILITY(U,$J,358.3,16295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16295,1,3,0)
 ;;=3^Promyelocytic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16295,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,16295,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,16296,0)
 ;;=C92.41^^64^785^14
 ;;^UTILITY(U,$J,358.3,16296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16296,1,3,0)
 ;;=3^Promyelocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16296,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,16296,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,16297,0)
 ;;=C92.50^^64^785^11
 ;;^UTILITY(U,$J,358.3,16297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16297,1,3,0)
 ;;=3^Myelomonocytic Leumkemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16297,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,16297,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,16298,0)
 ;;=C92.51^^64^785^10
 ;;^UTILITY(U,$J,358.3,16298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16298,1,3,0)
 ;;=3^Myelomonocytic Leumkemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16298,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,16298,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,16299,0)
 ;;=C92.00^^64^785^4
 ;;^UTILITY(U,$J,358.3,16299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16299,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16299,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,16299,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,16300,0)
 ;;=C92.01^^64^785^3
 ;;^UTILITY(U,$J,358.3,16300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16300,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16300,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,16300,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,16301,0)
 ;;=C92.10^^64^785^7
 ;;^UTILITY(U,$J,358.3,16301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16301,1,3,0)
 ;;=3^Myeloid Leukemia BCR/ABL-Positive,Chr,Not in Remission
 ;;^UTILITY(U,$J,358.3,16301,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,16301,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,16302,0)
 ;;=C92.11^^64^785^6
 ;;^UTILITY(U,$J,358.3,16302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16302,1,3,0)
 ;;=3^Myeloid Leukemia BCR/ABL-Positive,Chr,In Remission
 ;;^UTILITY(U,$J,358.3,16302,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,16302,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,16303,0)
 ;;=C92.20^^64^785^9
 ;;^UTILITY(U,$J,358.3,16303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16303,1,3,0)
 ;;=3^Myeloid Leukemia BCR/ABL-neg,Atyp Chr,Not in Remission
 ;;^UTILITY(U,$J,358.3,16303,1,4,0)
 ;;=4^C92.20
 ;;^UTILITY(U,$J,358.3,16303,2)
 ;;=^5001795
 ;;^UTILITY(U,$J,358.3,16304,0)
 ;;=C92.21^^64^785^8
 ;;^UTILITY(U,$J,358.3,16304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16304,1,3,0)
 ;;=3^Myeloid Leukemia BCR/ABL-neg,Atyp Chr,In Remission
 ;;^UTILITY(U,$J,358.3,16304,1,4,0)
 ;;=4^C92.21
 ;;^UTILITY(U,$J,358.3,16304,2)
 ;;=^5001796
 ;;^UTILITY(U,$J,358.3,16305,0)
 ;;=D46.9^^64^785^5
 ;;^UTILITY(U,$J,358.3,16305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16305,1,3,0)
 ;;=3^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,16305,1,4,0)
 ;;=4^D46.9
 ;;^UTILITY(U,$J,358.3,16305,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,16306,0)
 ;;=D45.^^64^785^12
 ;;^UTILITY(U,$J,358.3,16306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16306,1,3,0)
 ;;=3^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,16306,1,4,0)
 ;;=4^D45.
 ;;^UTILITY(U,$J,358.3,16306,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,16307,0)
 ;;=D75.1^^64^785^13
 ;;^UTILITY(U,$J,358.3,16307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16307,1,3,0)
 ;;=3^Polycythemia,Secondary
 ;;^UTILITY(U,$J,358.3,16307,1,4,0)
 ;;=4^D75.1
 ;;^UTILITY(U,$J,358.3,16307,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,16308,0)
 ;;=D68.51^^64^785^1
 ;;^UTILITY(U,$J,358.3,16308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16308,1,3,0)
 ;;=3^Activated Protein C Resistance
 ;;^UTILITY(U,$J,358.3,16308,1,4,0)
 ;;=4^D68.51
 ;;^UTILITY(U,$J,358.3,16308,2)
 ;;=^5002358
 ;;^UTILITY(U,$J,358.3,16309,0)
 ;;=D68.52^^64^785^16
 ;;^UTILITY(U,$J,358.3,16309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16309,1,3,0)
 ;;=3^Prothrombin Gene Mutation
 ;;^UTILITY(U,$J,358.3,16309,1,4,0)
 ;;=4^D68.52
 ;;^UTILITY(U,$J,358.3,16309,2)
 ;;=^5002359
 ;;^UTILITY(U,$J,358.3,16310,0)
 ;;=D68.59^^64^785^17
 ;;^UTILITY(U,$J,358.3,16310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16310,1,3,0)
 ;;=3^Thrombophilia,Primary,Other
 ;;^UTILITY(U,$J,358.3,16310,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,16310,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,16311,0)
 ;;=D68.62^^64^785^2
 ;;^UTILITY(U,$J,358.3,16311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16311,1,3,0)
 ;;=3^Lupus Anticoagulant Syndrome
 ;;^UTILITY(U,$J,358.3,16311,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,16311,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,16312,0)
 ;;=D72.9^^64^785^18
 ;;^UTILITY(U,$J,358.3,16312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16312,1,3,0)
 ;;=3^White Blood Cell Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,16312,1,4,0)
 ;;=4^D72.9
 ;;^UTILITY(U,$J,358.3,16312,2)
 ;;=^5002381
 ;;^UTILITY(U,$J,358.3,16313,0)
 ;;=Z85.038^^64^786^15
 ;;^UTILITY(U,$J,358.3,16313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16313,1,3,0)
 ;;=3^Personal Hx Malig Neop Large Intestine
 ;;^UTILITY(U,$J,358.3,16313,1,4,0)
 ;;=4^Z85.038
 ;;^UTILITY(U,$J,358.3,16313,2)
 ;;=^5063399
 ;;^UTILITY(U,$J,358.3,16314,0)
 ;;=Z85.51^^64^786^3
 ;;^UTILITY(U,$J,358.3,16314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16314,1,3,0)
 ;;=3^Personal Hx Malig Neop Bladder
 ;;^UTILITY(U,$J,358.3,16314,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,16314,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,16315,0)
 ;;=Z85.830^^64^786^4
 ;;^UTILITY(U,$J,358.3,16315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16315,1,3,0)
 ;;=3^Personal Hx Malig Neop Bone
 ;;^UTILITY(U,$J,358.3,16315,1,4,0)
 ;;=4^Z85.830
 ;;^UTILITY(U,$J,358.3,16315,2)
 ;;=^5063444
 ;;^UTILITY(U,$J,358.3,16316,0)
 ;;=Z85.841^^64^786^5
